| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M al-Maskari, J Gebbie, P Kendall-Taylo. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clinical endocrinology. vol 45. issue 4. 1997-01-02. PMID:8959079. |
previous studies have shown that somatostatin analogues such as octreotide and lanreotide are effective in suppressing gh and igf-i levels in acromegaly, but the mode of administration and the frequency of injections were inconvenient for the patients. |
1997-01-02 |
2023-08-12 |
Not clear |
| M al-Maskari, J Gebbie, P Kendall-Taylo. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clinical endocrinology. vol 45. issue 4. 1997-01-02. PMID:8959079. |
we have evaluated the effects of a new slow-release (sr), long-acting formulation of lanreotide, a somatostatin analogue, on clinical, biochemical and safety responses in acromegaly. |
1997-01-02 |
2023-08-12 |
Not clear |
| A I Günal, A Işik, H Celiker, O Eren, H Celebi, S Y Günal, C Lülec. Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections. Heart (British Cardiac Society). vol 76. issue 5. 1996-12-20. PMID:8944587. |
octreotide, a long acting somatostatin analogue, can prevent the stimulating effect of growth factors and decrease the left ventricular mass in patients with acromegaly. |
1996-12-20 |
2023-08-12 |
Not clear |
| M Giusti, G Gussoni, C M Cuttica, G Giordan. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. The Journal of clinical endocrinology and metabolism. vol 81. issue 6. 1996-12-11. PMID:8964833. |
the objective of the study was to determine the tolerability and effectiveness of the slow release (sr) somatostatin analog lanreotide in active acromegaly. |
1996-12-11 |
2023-08-12 |
human |
| M Giusti, G Gussoni, C M Cuttica, G Giordan. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. The Journal of clinical endocrinology and metabolism. vol 81. issue 6. 1996-12-11. PMID:8964833. |
the use of a new sustained release formulation of somatostatin analog is clearly advantageous in improving patient compliance with medical treatment for acromegaly. |
1996-12-11 |
2023-08-12 |
human |
| K Prank, M Kloppstech, S J Nowlan, T J Sejnowski, G Braban. Self-organized segmentation of time series: separating growth hormone secretion in acromegaly from normal controls. Biophysical journal. vol 70. issue 6. 1996-12-10. PMID:8744293. |
the pulsatile pattern of growth hormone (gh) secretion was assessed by sampling blood every 10 min over 24 h in healthy subjects (n = 10) under normal food intake and under fasting conditions (n = 6) and in patients with a gh-producing tumor (acromegaly, n = 6), before and after treatment with the somatostatin analog octreotide. |
1996-12-10 |
2023-08-12 |
human |
| M C Sheppard, P M Stewar. Treatment options for acromegaly. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769385. |
treatment options for acromegaly include surgical removal of the adenoma, radiotherapy, or pharmacological reduction of growth hormone (gh) levels by dopamine agonists or somatostatin analogs. |
1996-12-10 |
2023-08-12 |
human |
| G Toli. The role of somatostatin agonistic analogs in the treatment of acromegaly. Metabolism: clinical and experimental. vol 45. issue 8 Suppl 1. 1996-12-10. PMID:8769400. |
the role of somatostatin agonistic analogs in the treatment of acromegaly. |
1996-12-10 |
2023-08-12 |
Not clear |
| K Sato, K Takamatsu, K Hashimot. Short-term effects of octreotide on glucose tolerance in patients with acromegaly. Endocrine journal. vol 42. issue 6. 1996-11-14. PMID:8822314. |
to elucidate the short-term effects of octreotide, a somatostatin analogue, on glucose tolerance in acromegaly, the plasma glucose and insulin responses to a 75-g oral glucose tolerance test (75-g ogtt) were examined in 6 patients. |
1996-11-14 |
2023-08-12 |
Not clear |
| S L Jones, S Patchett, J V Anderson, M J Farthing, G M Besser, J A Was. Prevalence of Helicobacter pylori in acromegalic patients during treatment with octreotide. Clinical endocrinology. vol 43. issue 6. 1996-10-15. PMID:8736269. |
octreotide, a synthetic long-acting analogue of somatostatin, now has an established role in the treatment of acromegaly. |
1996-10-15 |
2023-08-12 |
Not clear |
| G Sassola. Medical therapy with somatostatin analogues for acromegaly. European journal of endocrinology. vol 133. issue 6. 1996-02-22. PMID:8548050. |
medical therapy with somatostatin analogues for acromegaly. |
1996-02-22 |
2023-08-12 |
Not clear |
| P Avagnina, M Martini, M Terzolo, G Sansoé, P Peretti, M Tinivella, A Pia, G Molino, A Angel. Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. Metabolism: clinical and experimental. vol 45. issue 1. 1996-02-12. PMID:8544766. |
functional liver mass and functional liver plasma flow (flpf) were assessed in 11 patients with clinical features of acromegaly by determining galactose elimination capacity (gec) and extrarenal clearance of sorbitol, before and 5 to 7 months after treatment with the long-acting somatostatin analog, octreotide (150 to 600 micrograms/d in three subcutaneous injections). |
1996-02-12 |
2023-08-12 |
Not clear |
| P M Stewart, K F Kane, S E Stewart, I Lancranjan, M C Sheppar. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 11. 1995-12-28. PMID:7593436. |
depot long-acting somatostatin analog (sandostatin-lar) is an effective treatment for acromegaly. |
1995-12-28 |
2023-08-12 |
Not clear |
| P M Stewart, K F Kane, S E Stewart, I Lancranjan, M C Sheppar. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 11. 1995-12-28. PMID:7593436. |
octreotide (sandostatin) is a synthetic analog of somatostatin, an endogenous gh inhibitory peptide that has been used as an adjunct to surgery and radiotherapy in the treatment of acromegaly. |
1995-12-28 |
2023-08-12 |
Not clear |
| S Ezzat, D A Redelmeier, M Gnehm, A G Harri. A prospective multicenter octreotide dose response study in the treatment of acromegaly. Journal of endocrinological investigation. vol 18. issue 5. 1995-11-30. PMID:7594225. |
the somatostatin analog octreotide has proven to be an effective form of treatment for various hypersecretory states including acromegaly. |
1995-11-30 |
2023-08-12 |
human |
| W W de Herder, P Uitterlinden, A J van der Lely, L J Hofland, S W Lambert. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly. European journal of endocrinology. vol 133. issue 2. 1995-10-02. PMID:7544670. |
in conclusion, octreotide induces in acromegaly the production of igfbp-1, which occurs independently of the number of somatostatin receptors on the gh-secreting pituitary adenoma. |
1995-10-02 |
2023-08-12 |
Not clear |
| K Haraguchi, M Ohtaka, K Takazawa, T Endo, T Onay. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly. Endocrine journal. vol 42. issue 2. 1995-09-01. PMID:7627275. |
desensitization to somatostatin analogue (octreotide) observed in a patient with acromegaly. |
1995-09-01 |
2023-08-12 |
Not clear |
| A G Harris, S P Kokoris, S Ezza. Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. Journal of clinical pharmacology. vol 35. issue 1. 1995-06-22. PMID:7751414. |
this review evaluates the efficacy, tolerability, and safety of continuous subcutaneous infusion (csi) relative to intermittent subcutaneous injection (isi) of the somatostatin analog, octreotide in the treatment of acromegaly. |
1995-06-22 |
2023-08-12 |
Not clear |
| J A McKnight, D R McCance, B Sheridan, A B Atkinso. Four years' treatment of resistant acromegaly with octreotide. European journal of endocrinology. vol 132. issue 4. 1995-05-15. PMID:7711880. |
this study was designed to ascertain the long-term safety and efficacy profile of the somatostatin analogue octreotide as treatment of refractory acromegaly. |
1995-05-15 |
2023-08-12 |
Not clear |
| C Boucekkine, F Catus, J Blumberg-Tick, M Pholséna, P Chanson, G Schaiso. [Treatment of acromegaly with a new slow release somatostatin analog, lanreotide]. Annales d'endocrinologie. vol 55. issue 6. 1995-03-23. PMID:7864583. |
[treatment of acromegaly with a new slow release somatostatin analog, lanreotide]. |
1995-03-23 |
2023-08-12 |
Not clear |